title: The Ayurvedic Medicine Salacia oblonga Attenuates Diabetic Renal Fibrosis in Rats: Suppression of Angiotensin II/AT1 Signaling.
abstract: In human diabetic nephropathy, the extent of tubulointerstitial fibrosis is the leading cause of end-stage renal disease; fibrosis is closely correlated with renal dysfunction. Although a wide array of medicinal plants play a role in the prevention and treatment of diabetes, there are few reports of the application of herbal medicines in amelioration of renal fibrosis, or the underlying mechanisms by which such benefits are mediated. The efficacy of the Ayurvedic antidiabetic medicine Salacia oblonga (SO) root on rat renal fibrosis was investigated. An aqueous extract from SO (100 mg/kg, p.o., 6 weeks) diminished renal glomerulosclerosis and interstitial fibrosis in Zucker diabetic fatty (ZDF) rats, as revealed by van Giesen-staining. SO also reduced renal salt-soluble, acid-soluble and salt-insoluble collagen contents. These changes were accompanied by normalization of hypoalbuminemia and BUN. Gene profiling revealed that the increase in transcripts encoding the glomerulosclerotic mediators collagen I, collagen IV, fibronectin, angiotensin II type 1 receptor (AT1), transforming growth factor (TGF)-β1, plasminogen activator inhibitor (PAI)-1 observed in ZDF rat kidney was suppressed by SO. In rat-derived mesangial cells, similar to the effect of the AT1 antagonist telmisartan, SO and its major component mangiferin suppressed the stimulatory effect of angiotensin II on proliferation and increased mRNA expression and/or activities of collagen I, collagen IV, fibronectin, AT1, TGF-β1 and PAI-1. Considered together the present findings demonstrate that SO attenuates diabetic renal fibrosis, at least in part by suppressing anigiotensin II/AT1 signaling. Further, it now emerges that mangiferin is an effective antifibrogenic agent.
authors.affiliation: School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
authors.forename: Lan
authors.initials: L
authors.lastname: He
authors.forename: Yanfei
authors.initials: Y
authors.lastname: Qi
authors.forename: Xianglu
authors.initials: X
authors.lastname: Rong
authors.forename: Jianmin
authors.initials: J
authors.lastname: Jiang
authors.forename: Qinglin
authors.initials: Q
authors.lastname: Yang
authors.forename: Johji
authors.initials: J
authors.lastname: Yamahara
authors.forename: Michael
authors.initials: M
authors.lastname: Murray
authors.forename: Yuhao
authors.initials: Y
authors.lastname: Li
references.citation: Kidney Int. 1994 Jan;45(1):177-84
references.pmid: 8127007
references.citation: Kidney Int. 2006 Dec;70(11):1914-9
references.pmid: 16985515
references.citation: Diabetes. 1994 Aug;43(8):1046-51
references.pmid: 8039599
references.citation: Circulation. 2002 Sep 24;106(13):1722-8
references.pmid: 12270869
references.citation: Evid Based Complement Alternat Med. 2005 Dec;2(4):465-73
references.pmid: 16322803
references.citation: Evid Based Complement Alternat Med. 2008 Mar;5(1):1-2
references.pmid: 18317542
references.citation: Kidney Int. 2002 Jan;61(1 Suppl):S106-9
references.pmid: 11841622
references.citation: Life Sci. 2004 Aug 20;75(14):1735-46
references.pmid: 15268973
references.citation: Evid Based Complement Alternat Med. 2008 Jun;5(2):121-2
references.pmid: 18604248
references.citation: Diabetes Obes Metab. 2008 Jul;10(7):574-85
references.pmid: 17645561
references.citation: J Clin Invest. 1994 Jun;93(6):2431-7
references.pmid: 8200978
references.citation: Yakugaku Zasshi. 2001 May;121(5):371-8
references.pmid: 11360491
references.citation: Diabetes Metab Res Rev. 2008 Sep;24(6):498-506
references.pmid: 18613221
references.citation: Am J Nephrol. 2008;28(4):548-54
references.pmid: 18239381
references.citation: Am J Physiol Renal Physiol. 2002 Aug;283(2):F209-20
references.pmid: 12110504
references.citation: J Clin Invest. 2003 Aug;112(3):326-8
references.pmid: 12897200
references.citation: EMBO J. 1987 May;6(5):1281-6
references.pmid: 3111844
references.citation: Pathol Res Pract. 1980;167(2-4):204-16
references.pmid: 7433232
references.citation: J Clin Invest. 2006 Feb;116(2):288-96
references.pmid: 16453013
references.citation: Hypertension. 2001 Sep;38(3 Pt 2):635-8
references.pmid: 11566946
references.citation: Curr Opin Nephrol Hypertens. 2004 May;13(3):279-84
references.pmid: 15073485
references.citation: Diabetes. 1999 Oct;48(10):2066-73
references.pmid: 10512375
references.citation: Phytother Res. 2007 Jan;21(1):1-16
references.pmid: 16927447
references.citation: Nephrol Dial Transplant. 2006 Jan;21(1):16-20
references.pmid: 16280370
references.citation: Life Sci. 2008 May 23;82(21-22):1045-9
references.pmid: 18433791
references.citation: Am J Nephrol. 2003 Jul-Aug;23(4):222-8
references.pmid: 12840598
references.citation: J Am Soc Nephrol. 1995 Jan;5(7):1492-7
references.pmid: 7703388
references.citation: Am J Pathol. 1992 Jan;140(1):95-107
references.pmid: 1731533
references.citation: J Clin Invest. 2007 Mar;117(3):524-9
references.pmid: 17332879
references.citation: J Vasc Surg. 2005 Jul;42(1):140-8
references.pmid: 16012463
references.citation: Circulation. 2005 Apr 19;111(15):1962-9
references.pmid: 15837950
references.citation: Kidney Int. 1993 Mar;43(3):661-7
references.pmid: 8455365
references.citation: Diabetes. 1989 Sep;38(9):1077-81
references.pmid: 2670639
references.citation: Toxicol Appl Pharmacol. 2006 Feb 1;210(3):225-35
references.pmid: 15975614
references.citation: Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):78-85
references.pmid: 16129467
references.citation: Kidney Int. 1999 Nov;56(5):1627-37
references.pmid: 10571771